ARCHIVES

Mendelsohn Defends ImClone’s Actions And His Role In Development of C225

This article is from The Cancer Letter archive.

Vol. 28 No. 38 | October 18, 2002

Download PDF Visit The Full Archive

Related Articles

Tafinlar Subgroup Data Shows Median OS of 20 Months

October 31, 2014

Cancer Meetings Listed for Next Three Months

January 19, 1996

Nursing Center Moves Onto Campus

May 9, 1986

Bladder Cancer Survival Rate Rises With Neoadjuvant Chemo

September 26, 2003

NIH Expands Minority Biomedical Research Training

July 11, 1975

NCI Unveils Checklist for Omics Studies

February 7, 2013